Shandong Xinhua’s Generic Drug Receives Key Approval
Company Announcements

Shandong Xinhua’s Generic Drug Receives Key Approval

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical announced that its calcium gluconate injection has successfully passed the quality and efficacy evaluation for generic drugs by the National Medical Products Administration. This approval marks a significant step for the company in the pharmaceutical market, enhancing its product portfolio and potential market reach. Investors may find this development promising as it could lead to increased competitiveness and sales growth.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharma Secures Key Drug Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Gains Approval for Pentazocine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App